1Senthil PK. Cancer pain: A critical review of mec- hanism-based classification and physical therapy management in palliative care. Indian J Palliat Care. 2011, 17 : 116 - 126.
2Brawley OW, Smith DE, Kirch RA. Taking action to ease suffering: Advancing cancer pain control as a healthcare priority. CA Cancer J Clin, 2009, 59 : 285 - 289.
3Singh DP. Quality of life in cancer patients receivi- ng palliative care. Indian J Palliat Care, 2010, 16 : 36 - 43.
4Juver JP, Vercosa N. Depression in patients with advanced cancer and pain. Rev Bras Anestesiol, 2008, 58 : 287 - 298.
5Mellon S, Northouse LL, Weiss LK, et al. A popul- ation-based study of the quality of life of cancer survivors and their family caregivers. Cancer Nurs, 2006, 29 : 120 - 131.
6Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic ef- fect of tram adol in rats with mononeuropathic pain. Pharmacol Biochem Behav, 2007, 88 : 171- 178.
7Dunn GP, Old L J, Schrei ber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004, 21:137 - 148.
8Grivennikov SI, Greten FR, Karin M. Immunity, infla- mmation, and cancer. Cell, 2010,140:883 - 899.
9Yu MC, Su LL, Zou L, et al. An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells. Nat Immunol,2008, 9:898 - 907.
10Han Y, Zhang M, Li N, et al. KLRL1, a novel killer cell lectinlike receptor, inhibits natural killer cell cytotoxicity. Blood, 2004,104:2858 - 2866.
